February 21, 2018 / 6:22 AM / 10 months ago

BRIEF-Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%

Feb 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA:

* SARTORIUS STEDIM BIOTECH TARGETS CONTINUED PROFITABLE GROWTH - SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025

* SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025

* NEW MEDIUM-TERM TARGETS: UNDERLYING EBITDA MARGIN OF ABOUT 30 PERCENT IN 2025

* 2017 UNDERLYING EBITDA INCREASED BY 2.2% TO €294.9 MILLION‍​

* 2017 INCREASE IN SALES REVENUE BY AROUND 4.1% TO EUR 1,081.0 MILLION

* FORECASTS A RISE IN SALES REVENUE BY ABOUT 7% TO 10% IN 2018

* SEES 2018 INCREASE OF UNDERLYING EBITDA MARGIN BY APPROX. 0.5 PERCENTAGE POINTS OVER PRIOR-YEAR FIGURE.

* OUTLOOK 2018 CAPEX IS EXPECTED TO BE AT APPROX. 15% OF SALES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below